Division of Catalyst Biosciences Inc.
Latest From Targacept Inc.
Selecta Biosciences Inc., which is developing a novel class of targeted antigen-specific immune therapies using Synthetic Vaccine Particles (SVP), has appointed Dr Earl Sands as chief medical officer. Prior to joining Selecta, Sands was most recently chief medical officer of Targacept.
Bristol increases R&D emphasis on gene therapy through a collaboration with Dutch biotech uniQure, paying $50 million up front with numerous potential earn-outs. Astellas becomes the third pharma to sign a “Moon Shots” partnership with MD Anderson Cancer Center.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.
Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Catalyst Biosciences Inc.
- Senior Management
Mauri K Hodges, VP, Fin. & Admin., CFO
Scott N Cullison, VP, Bus. Dev.
Merouane Bencherif, MD, PhD, SVP & Sr. Scientific Fellow
- Contact Info
Phone: (336) 480-2100
100 North Main St.
Winston-Salem, NC 27101-4072
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.